These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Two bcr/abl fusion gene products, P210bcr/abl and P190bcr/abl, are equally sensitive to the protein tyrosine phosphatase of mature granulocytes. Nishimura J; Okamura J; Shibata K; Takahira H; Yufu Y; Kato S; Hirata J; Umemura T; Nawata H Int J Hematol; 1991 Dec; 54(6):471-8. PubMed ID: 1793829 [TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840 [TBL] [Abstract][Full Text] [Related]
4. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544 [TBL] [Abstract][Full Text] [Related]
5. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226 [TBL] [Abstract][Full Text] [Related]
6. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients. Maxwell SA; Kurzrock R; Parsons SJ; Talpaz M; Gallick GE; Kloetzer WS; Arlinghaus RB; Kouttab NM; Keating MJ; Gutterman JU Cancer Res; 1987 Mar; 47(6):1731-9. PubMed ID: 2434223 [TBL] [Abstract][Full Text] [Related]
7. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Okuda K; Golub TR; Gilliland DG; Griffin JD Oncogene; 1996 Sep; 13(6):1147-52. PubMed ID: 8808688 [TBL] [Abstract][Full Text] [Related]
8. Phosphotyrosine phosphatase activity prevents the detection of P210bcr/abl protein in mature cells in chronic myelogenous leukemia even by an immunoblotting technique. Shibata K; Nishimura J; Takahira H; Nawata H Leukemia; 1989 Sep; 3(9):615-9. PubMed ID: 2474729 [TBL] [Abstract][Full Text] [Related]
9. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Danhauser-Riedl S; Warmuth M; Druker BJ; Emmerich B; Hallek M Cancer Res; 1996 Aug; 56(15):3589-96. PubMed ID: 8758931 [TBL] [Abstract][Full Text] [Related]
10. A novel 53 kDa protein complexed with P210bcr-abl in human chronic myelogenous leukemia cells. Li WJ; Kloetzer WS; Arlinghaus RB Oncogene; 1988 Jun; 2(6):559-66. PubMed ID: 3133627 [TBL] [Abstract][Full Text] [Related]
11. Differential interaction and activation of Rho family GTPases by p210bcr-abl and p190bcr-abl. Harnois T; Constantin B; Rioux A; Grenioux E; Kitzis A; Bourmeyster N Oncogene; 2003 Sep; 22(41):6445-54. PubMed ID: 14508524 [TBL] [Abstract][Full Text] [Related]
13. Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. Carlesso N; Griffin JD; Druker BJ Oncogene; 1994 Jan; 9(1):149-56. PubMed ID: 8302574 [TBL] [Abstract][Full Text] [Related]
14. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene. Snyder DS; Wu Y; McMahon R; Yu L; Rossi JJ; Forman SJ Biol Blood Marrow Transplant; 1997 Oct; 3(4):179-86. PubMed ID: 9360779 [TBL] [Abstract][Full Text] [Related]
15. Establishment, characterization, and chromosomal analysis of new leukemic cell lines derived from MT/p210bcr/abl transgenic mice. Honda H; Ohno S; Takahashi T; Takatoku M; Yazaki Y; Hirai H Exp Hematol; 1998 Mar; 26(3):188-97. PubMed ID: 9502614 [TBL] [Abstract][Full Text] [Related]
16. Expression of the chronic myelogenous leukemia-associated p210bcr/abl oncoprotein in a murine IL-3 dependent myeloid cell line. Laneuville P; Heisterkamp N; Groffen J Oncogene; 1991 Feb; 6(2):275-82. PubMed ID: 1705688 [TBL] [Abstract][Full Text] [Related]
17. P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation. Wilson-Rawls J; Xie S; Liu J; Laneuville P; Arlinghaus RB Cancer Res; 1996 Aug; 56(15):3426-30. PubMed ID: 8758906 [TBL] [Abstract][Full Text] [Related]
18. Crk-associated substrate lymphocyte type regulates myeloid cell motility and suppresses the progression of leukemia induced by p210Bcr/Abl. Seo S; Nakamoto T; Takeshita M; Lu J; Sato T; Suzuki T; Kamikubo Y; Ichikawa M; Noda M; Ogawa S; Honda H; Oda H; Kurokawa M Cancer Sci; 2011 Dec; 102(12):2109-17. PubMed ID: 21848808 [TBL] [Abstract][Full Text] [Related]
19. Tyrosine phosphorylation of murine Crkl. de Jong R; Haataja L; Voncken JW; Heisterkamp N; Groffen J Oncogene; 1995 Oct; 11(8):1469-74. PubMed ID: 7478571 [TBL] [Abstract][Full Text] [Related]
20. BCR/ABL modulates the cytokine and retinoic acid response of c-Rel in human myeloid cells. Neumann M; Wilisch A; Ma BC; Druker BJ; Serfling E; Franza BR Anticancer Res; 1996; 16(3A):1075-83. PubMed ID: 8702216 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]